stockrowArdelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +27.5%
- Free cash flow
- +938.8%
- Total debt
- +24.8%
Quarter to September 2026, against a year earlier
Follow ARDX
Alert me
Ardelyx, Inc. (ARDX) EV/Sales
As of 6 November 2026, Ardelyx, Inc. (ARDX) trades at a EV/Sales of 1.5×. Over the past ten years it has ranged from −13.6× (December 2018) to 1,054× (September 2019); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | 0.18% |
| FY2024 | 3.4× | (65.73%) |
| FY2023 | 9.8× | 48.06% |
| FY2022 | 6.6× | 67.27% |
| FY2021 | 4.0× | (93.25%) |
| FY2020 | 58.6× | 9.72% |
| FY2019 | 53.4× | — |
| FY2018 | −7.0× | — |
| FY2017 | 6.5× | (35.65%) |
| FY2015 | 10.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.8× | (35.22%) |
| Jun 2026 | 2.8× | (18.29%) |
| Mar 2026 | 3.4× | 1.82% |
| Dec 2025 | 3.4× | 1.55% |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| ARDX Ardelyx, Inc. | 1.5× |
| MGTX MeiraGTx Holdings PLC compare | 2.0× |
| OABI OmniAb, Inc. compare | 14.5× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | 17.4× |
| ALMS Alumis Inc. compare | 36.0× |
| PRME Prime Medicine, Inc. compare | 177× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)